ebomi
Colour theme
Sign in
Insider · CIK 0001606074

Svennilson Peter

CIK 0001606074 Name as filed on the most recent filing

Filed as Svennilson Peter (90)

254 transaction lines · from 90 filings · filed 2014-07-31 to 2026-02-26 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.

How this page attributes a trade

A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.

01

Issuers this insider has filed against

Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-27 05:24 UTC.

No issuer is recorded

The catalog holds no filing linking this CIK to an issuer.

02

Transactions

Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.

90 transactions · Newest transaction date first, id breaking the tie.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-27 05:24 UTC.

Transactions filed by this insider
Direction Date Code Company Value USD Filing
2019-11-11 P, Open-market purchase NGM Biopharmaceuticals IncNGM 180, acquired Open Form 4 filing 0001209191-19-056445
2019-11-04 P, Open-market purchase NGM Biopharmaceuticals IncNGM 100,824, acquired Open Form 4 filing 0001209191-19-055555
2019-11-04 P, Open-market purchase Rapt Therapeutics, Inc.RAPT 7,500,000, acquired Open Form 4 filing 0001209191-19-054999
2019-10-23 P, Open-market purchase NGM Biopharmaceuticals IncNGM 24,752, acquired Open Form 4 filing 0001209191-19-053950
2019-10-22 P, Open-market purchase NGM Biopharmaceuticals IncNGM 27,600, acquired Open Form 4 filing 0001209191-19-053950
2019-10-21 P, Open-market purchase NGM Biopharmaceuticals IncNGM 518,196, acquired Open Form 4 filing 0001209191-19-053738
2019-10-18 P, Open-market purchase NGM Biopharmaceuticals IncNGM 392,000, acquired Open Form 4 filing 0001209191-19-053738
2019-10-17 P, Open-market purchase NGM Biopharmaceuticals IncNGM 72,407, acquired Open Form 4 filing 0001209191-19-053738
2019-10-16 P, Open-market purchase NGM Biopharmaceuticals IncNGM 358,074, acquired Open Form 4 filing 0001209191-19-053340
2019-10-15 P, Open-market purchase NGM Biopharmaceuticals IncNGM 342,292, acquired Open Form 4 filing 0001209191-19-053340
2019-10-14 P, Open-market purchase NGM Biopharmaceuticals IncNGM 361,564, acquired Open Form 4 filing 0001209191-19-053340
2019-10-11 P, Open-market purchase NGM Biopharmaceuticals IncNGM 187,343, acquired Open Form 4 filing 0001606074-19-000024
2019-10-10 P, Open-market purchase NGM Biopharmaceuticals IncNGM 186,102, acquired Open Form 4 filing 0001606074-19-000024
2019-10-09 P, Open-market purchase NGM Biopharmaceuticals IncNGM 181,848, acquired Open Form 4 filing 0001606074-19-000024
2019-10-03 P, Open-market purchase Constellation Pharmaceuticals IncCNST 2 lines 11,999,994, acquired Open Form 4 filing 0001347769-19-000016
2019-08-09 P, Open-market purchase NGM Biopharmaceuticals IncNGM 2,126, acquired Open Form 4 filing 0000899243-19-021511
2019-08-08 P, Open-market purchase NGM Biopharmaceuticals IncNGM 168, acquired Open Form 4 filing 0000899243-19-021511
2019-08-07 P, Open-market purchase NGM Biopharmaceuticals IncNGM 3,143,000, acquired Open Form 4 filing 0000899243-19-021511
2019-08-06 P, Open-market purchase NGM Biopharmaceuticals IncNGM 4,328, acquired Open Form 4 filing 0001606074-19-000021
2019-08-05 P, Open-market purchase NGM Biopharmaceuticals IncNGM 81,400, acquired Open Form 4 filing 0001606074-19-000021
2019-08-02 P, Open-market purchase NGM Biopharmaceuticals IncNGM 24,898, acquired Open Form 4 filing 0001606074-19-000020
2019-08-01 P, Open-market purchase NGM Biopharmaceuticals IncNGM 36,346, acquired Open Form 4 filing 0001606074-19-000020
2019-07-30 P, Open-market purchase NGM Biopharmaceuticals IncNGM 123,195, acquired Open Form 4 filing 0001606074-19-000019
2019-07-29 P, Open-market purchase NGM Biopharmaceuticals IncNGM 260,727, acquired Open Form 4 filing 0001606074-19-000019
2019-07-26 P, Open-market purchase NGM Biopharmaceuticals IncNGM 408,634, acquired Open Form 4 filing 0001606074-19-000018
2019-07-25 P, Open-market purchase NGM Biopharmaceuticals IncNGM 411,294, acquired Open Form 4 filing 0001606074-19-000018
2019-07-24 P, Open-market purchase NGM Biopharmaceuticals IncNGM 392,502, acquired Open Form 4 filing 0001606074-19-000018
2019-07-23 P, Open-market purchase NGM Biopharmaceuticals IncNGM 410,535, acquired Open Form 4 filing 0001606074-19-000017
2019-07-22 P, Open-market purchase NGM Biopharmaceuticals IncNGM 416,337, acquired Open Form 4 filing 0001606074-19-000017
2019-07-19 P, Open-market purchase NGM Biopharmaceuticals IncNGM 87,043, acquired Open Form 4 filing 0001606074-19-000017
2019-07-16 P, Open-market purchase NGM Biopharmaceuticals IncNGM 54,055, acquired Open Form 4 filing 0001606074-19-000016
2019-07-15 P, Open-market purchase NGM Biopharmaceuticals IncNGM 221,547, acquired Open Form 4 filing 0001606074-19-000016
2019-07-12 P, Open-market purchase NGM Biopharmaceuticals IncNGM 291,765, acquired Open Form 4 filing 0001606074-19-000015
2019-07-11 P, Open-market purchase NGM Biopharmaceuticals IncNGM 150,752, acquired Open Form 4 filing 0001606074-19-000015
2019-06-24 P, Open-market purchase NGM Biopharmaceuticals IncNGM 168,650, acquired Open Form 4 filing 0001606074-19-000014
2019-06-21 P, Open-market purchase NGM Biopharmaceuticals IncNGM 52,789, acquired Open Form 4 filing 0001606074-19-000013
2019-06-20 P, Open-market purchase NGM Biopharmaceuticals IncNGM 213,385, acquired Open Form 4 filing 0001606074-19-000013
2019-06-19 P, Open-market purchase NGM Biopharmaceuticals IncNGM 211,674, acquired Open Form 4 filing 0001606074-19-000013
2019-06-14 P, Open-market purchase NGM Biopharmaceuticals IncNGM 150,687, acquired Open Form 4 filing 0001606074-19-000012
2019-06-13 P, Open-market purchase NGM Biopharmaceuticals IncNGM 162,508, acquired Open Form 4 filing 0001606074-19-000012
2019-06-12 P, Open-market purchase NGM Biopharmaceuticals IncNGM 104,989, acquired Open Form 4 filing 0001606074-19-000012
2019-06-11 P, Open-market purchase NGM Biopharmaceuticals IncNGM 150,718, acquired Open Form 4 filing 0001606074-19-000011
2019-06-07 P, Open-market purchase NGM Biopharmaceuticals IncNGM 172,176, acquired Open Form 4 filing 0001606074-19-000011
2019-06-06 P, Open-market purchase NGM Biopharmaceuticals IncNGM 168,884, acquired Open Form 4 filing 0001606074-19-000010
2019-06-04 P, Open-market purchase NGM Biopharmaceuticals IncNGM 168,764, acquired Open Form 4 filing 0001606074-19-000010
2019-05-20 P, Open-market purchase NGM Biopharmaceuticals IncNGM 675,000, acquired Open Form 4 filing 0001606074-19-000009
2019-05-10 P, Open-market purchase NGM Biopharmaceuticals IncNGM 248,234, acquired Open Form 4 filing 0001606074-19-000008
2019-05-07 P, Open-market purchase NGM Biopharmaceuticals IncNGM 803,700, acquired Open Form 4 filing 0001606074-19-000007
2019-04-08 P, Open-market purchase NGM Biopharmaceuticals IncNGM 30,000,000, acquired Open Form 4 filing 0001209191-19-024274

This column is intentionally blank

No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.

Search the catalog
Codes on this page
P, Open-market purchase
Open-market purchase
Relationships on this page
D, Director
Director
%, Ten percent owner
Ten percent owner

Every value is as reported on the Form 4, totalled to the dollar. Share counts, the price per share and the full list of reporting owners are on each filing's own page, which every row here opens. A row marked n lines adds up that many filed lines of one filing, on one day, on one side of the market; a filing whose lines fall across two pages is left as its lines on both, so no total here is ever short.

What this insider's stored lines contain

Exact counts over every stored line for this entity. This is a statement of composition, not a filter: the only filter this page offers is the open-market one above, because that is the only one an index serves today.

  • Open-market purchase 70
  • Open-market sale 20
  • Option exercise 0
  • Grant or award 0
  • Tax withholding 0
  • Disposition to the issuer 0
  • In-the-money option exercise 0

How to cite this page

ebomi catalog. Svennilson Peter, insider transactions. Retrieved 2026-08-27 from https://ebomi.com/insider/0001606074

Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6

This page as JSON The JSON twin is shaped by the same read model as this page, so the two cannot disagree. Its envelope carries the canonical URL, the retrieval time, the coverage claim, and the licence statement.